Aldeyra Therapeu Stock Price, News & Analysis

Aldeyra Therapeutics (NASDAQ: ALDX) has completed enrollment in its Phase 3 INVIGORATE-2 clinical trial for reproxalap, a new treatment for allergic conjunctivitis. This investigational drug aims to provide relief for patients who currently rely on therapies with limited effectiveness and significant side effects. The trial involved 131 patients exposed to allergens in a controlled environment, with primary results focusing on patient-reported ocular itching. Top-line results are expected in the first half of 2023. Reproxalap has shown positive results in previous trials, demonstrating significant improvement in symptoms. The drug represents a novel therapeutic approach, with over 2,300 patients studied and minimal safety concerns reported.

Aldeyra Therapeutics announced the enrollment of the first patient in a Phase 2 clinical trial for ADX-629, an oral drug targeting atopic dermatitis. This multicenter trial will assess ADX-629's safety and efficacy in adults with varying severity of the condition. In Part 1, 10 patients will receive the drug for 90 days, with top-line results expected in the second half of 2023. Atopic dermatitis impacts over 16.5 million adults in the U.S., and ADX-629 could become the first oral RASP modulator for this condition. The drug has shown potential in other trials for conditions like psoriasis and COVID-19. Alongside atopic dermatitis, ADX-629 is being evaluated for chronic cough, nephrotic syndrome, and Sjögren-Larsson Syndrome, with results from additional trials also anticipated this year.

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) has completed enrollment for its Phase 2 clinical trial of ADX-629, an investigational RASP modulator for chronic cough treatment. The multicenter trial includes 51 patients with unexplained chronic cough, assessing safety as the primary endpoint, alongside secondary outcomes like cough frequency and quality of life. Top-line results are anticipated in the first half of 2023. ADX-629 aims to address a significant unmet medical need, with preliminary studies indicating elevated RASP levels in affected patients. The company's broader strategy involves developing therapies that modulate immune responses rather than targeting single proteins.

Aldeyra Therapeutics has completed enrollment in its Phase 2 clinical trial of ADX-2191, a methotrexate injection, for treating retinitis pigmentosa, a rare genetic eye disease. This trial involves eight patients with rhodopsin gene mutations receiving intravitreal doses for three months. The primary focus is on safety, while secondary endpoints assess changes in visual acuity and retinal function. The company aims to report top-line results in the first half of 2023. ADX-2191 has received orphan drug designation from the FDA, addressing an unmet medical need affecting over one million patients worldwide.

Aldeyra Therapeutics (Nasdaq: ALDX) reported significant developments and financial results for 2022, with key highlights including the Priority Review Designation for ADX-2191 to treat primary vitreoretinal lymphoma, with a PDUFA date set for June 21, 2023. The NDA for reproxalap to treat dry eye disease has a PDUFA date of November 23, 2023. Financially, cash and marketable securities totaled $174.3 million as of December 31, 2022. Despite a net loss of $62 million for the year, Aldeyra believes its current financial resources will fund operations into the second half of 2024, supporting ongoing clinical trials and potential commercial launches.

Aldeyra Therapeutics (ALDX) announced the FDA's acceptance of the New Drug Application (NDA) for ADX-2191, aimed at treating primary vitreoretinal lymphoma. The FDA granted Priority Review, with a PDUFA date set for June 21, 2023. ADX-2191 could become the first FDA-approved treatment for this rare cancer, with no approved alternatives currently available. The NDA is supported by extensive literature and recent Phase 3 GUARD Trial data, showing no serious adverse safety signals. Aldeyra plans to launch ADX-2191 in the U.S. in the second half of 2023, pending FDA approval.

Aldeyra Therapeutics, Inc. (ALDX) will host a conference call on March 9, 2023, at 8:00 a.m. ET to discuss its financial results for the year ended December 31, 2022, and recent corporate highlights. The call is accessible to both domestic and international callers with dedicated dial-in numbers. Investors can also access a live audio webcast of the conference through Aldeyra’s website, where the event will remain archived for 90 days. Aldeyra is a clinical-stage biotechnology company focused on therapies for immune-mediated diseases, with key product candidates under FDA review.